Figure 1 illustrates that, in both male and female patients diagnosed with type 2 diabetes, the glycemic markers HbA1c and fasting blood glucose (FBG) were significantly lower six months post-SGLT2 inhibitor treatment. Here, SLC5A2 is linked to type 2 diabetes mellitus.